Literature DB >> 32944166

Pronounced difference in Covid-19 antibody prevalence indicates cluster transmission in Stockholm, Sweden.

Åke Lundkvist1, Stefan Hanson2, Björn Olsen3.   

Abstract

The prevalence of COVID-19 antibodies on June 17-18, 2020 was investigated in two residential areas of Stockholm, Sweden. Among the residents in Norra Djurgårdsstaden, a newly built upper- and middle-class area of Stockholm, 4.1% of study participants had SARS-CoV-2-specific antibodies, while in Tensta, a highly segregated low-income area, 30% of the participants tested antibody positive.
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Entities:  

Keywords:  COVID-19; IgG; IgM; SARS-CoV-2; cluster transmission; rapid test

Year:  2020        PMID: 32944166      PMCID: PMC7480443          DOI: 10.1080/20008686.2020.1806505

Source DB:  PubMed          Journal:  Infect Ecol Epidemiol        ISSN: 2000-8686


COVID-19, caused by the novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has rapidly developed into a global pandemic [1]. By early July 2020, the total number of reported COVID-19 cases exceeded 11 million with more than half a million deaths [2], but the actual numbers are likely to be much higher, as testing and reporting are still limited in many regions. The major clinical symptoms of COVID-19, i.e. fever and dry cough, resemble those of respiratory illnesses caused by other viruses [3], while anosmia (loss of smell) and ageusia (loss of taste) have been noted as early and sometimes the only symptoms [4]. The virus has also been detected in completely asymptomatic individuals [5,6] and there are data indicating that the proportion of asymptomatic infections could be as high as 80% [7]. As in most parts of the world, COVID-19 has spread rapidly in Sweden, especially in larger cities, including the capital Stockholm. The number of deaths in COVID-19 is far higher in Sweden (n = 5,447, July 8, 2020), as compared to the compiled deaths in its neighbouring countries Norway, Denmark and Finland (n = 1,189 lethal cases, July 8, 2020) [2]. In a recent study, performed between May 30 and June 3, 2020, we noted differences in the COVID-19 antibody prevalence rates between different areas in Stockholm (population approx. 2.4 million individuals, our unpublished observation). Similar reports on clusters of SARS-CoV-2 infections have been published from e.g. China and Kuwait [8,9]. In the present study, we selected two areas in Stockholm with different socio-economic conditions: Norra Djurgårdsstaden (NDS), a new area located in the north-eastern inner city part of Stockholm, recently built with a mainly middle- to high-income population, and Tensta, a lower income highly segregated suburban area in northern Stockholm, built in the late 1960´s. Randomly selected individuals were tested at local temporary testing sites (June 17–18, 2020) using a COVID-19 IgG/IgM rapid test (Zhejiang Orient Gene Biotech Co Ltd, Huzhou, Zhejiang, China), which has been described and evaluated previously [10]. Our recent extended evaluation (using serum samples from 200 negative individuals and 100 COVID-19 patients) of this rapid test has revealed specificities for IgM and IgG of 100 and 95.5%, respectively and sensitivities close to 100% for both IgM and IgG (our unpublished observations). In addition to the antibody test results, age, gender, residence, Swedish mother tongue or not, and Swedish origin or not, were recorded. A written consent was provided by all participants, and ethical approval was obtained from the Swedish Ethical Review Authority (2020–02047). The study included 123 residents from NDS and 90 from Tensta (Table 1). The proportion of females were 58% and 29%, and the mean ages were 37y and 50y among the tested individuals in NDS and Tensta, respectively.
Table 1.

Summary of results.

ResidenceProportion of females (%)Mean age (years)Sweden as country of origin (%)Swedish as mother tongue (%)Total Ab positive (%)IgM only (%)IgM and IgG (%)IgG only (%)
Djurgårdsstaden (n = 123)583798.497.54.101.62.4
Tensta (n = 90)29501.11.130.01.18.820
Summary of results. Of the 123 tested individuals living in NDS, five (4.1%; 95% confidence interval (CI): ± 3.5%) were found positive for SARS-CoV-2 IgM and/or IgG (Table 1). None tested positive for IgM only, while three tested positive only for IgG. Of the 90 individuals tested in Tensta, 27 (30%; 95% CI: ± 9.7%) were found positive for SARS-CoV-2 IgM and/or IgG (Table 1). One individual tested positive for IgM only, while 18 were positive only for IgG. The majority (98.4%) of the tested individuals in NDS were of Swedish origin in contrast to only 1.1% in Tensta (Table 1). Although the number of tested individuals was limited in the present study, a clear and statistically significant (Fishers exact test, p < 0.001) difference in COVID-19 antibody prevalence was observed between the two residential areas, with only 4.1% antibody positivity in NDS as compared to 30% in Tensta, which is in line with earlier reports on COVID-19 super-spreaders and cluster transmission [8,9]. Cramped accommodation and generation housing may partly explain the significant difference in COVID-19 antibody prevalence rates between these two areas of Stockholm, suggesting a pronounced cluster transmission in Tensta. Another factor may be differences in working conditions, as it is likely that working from home has been much more common in NDS during the pandemic, while a large proportion of the residents in Tensta work in service professions, including transport and care. An additional potential explanation may be the fact that the translation of the recommendations from The Public Health Agency of Sweden concerning the safety measures and restrictions into e.g. Arabic, Tigrinya and Somali was severely delayed during the initial phase of the pandemic in Sweden. Our results indicated an urgent need for extensively increased testing capacity, both by PCR for detailed calculations of actual infection levels and by serology to estimate the immunity rates, as well as for contact-tracing/quarantine measures in order to control the pandemic in Sweden.
  8 in total

1.  Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'.

Authors:  Enrico Lavezzo; Elisa Franchin; Constanze Ciavarella; Gina Cuomo-Dannenburg; Luisa Barzon; Claudia Del Vecchio; Lucia Rossi; Riccardo Manganelli; Arianna Loregian; Nicolò Navarin; Davide Abate; Manuela Sciro; Stefano Merigliano; Ettore De Canale; Maria Cristina Vanuzzo; Valeria Besutti; Francesca Saluzzo; Francesco Onelia; Monia Pacenti; Saverio G Parisi; Giovanni Carretta; Daniele Donato; Luciano Flor; Silvia Cocchio; Giulia Masi; Alessandro Sperduti; Lorenzo Cattarino; Renato Salvador; Michele Nicoletti; Federico Caldart; Gioele Castelli; Eleonora Nieddu; Beatrice Labella; Ludovico Fava; Matteo Drigo; Katy A M Gaythorpe; Alessandra R Brazzale; Stefano Toppo; Marta Trevisan; Vincenzo Baldo; Christl A Donnelly; Neil M Ferguson; Ilaria Dorigatti; Andrea Crisanti
Journal:  Nature       Date:  2020-06-30       Impact factor: 49.962

2.  Covid-19: four fifths of cases are asymptomatic, China figures indicate.

Authors:  Michael Day
Journal:  BMJ       Date:  2020-04-02

3.  A Cluster of Novel Coronavirus Disease 2019 Infections Indicating Person-to-Person Transmission Among Casual Contacts From Social Gatherings: An Outbreak Case-Contact Investigation.

Authors:  Ye Shen; Wenjie Xu; Changwei Li; Andreas Handel; Leonardo Martinez; Feng Ling; Mark Ebell; Xiaofei Fu; Jinren Pan; Jiangping Ren; Weiling Gu; Enfu Chen
Journal:  Open Forum Infect Dis       Date:  2020-06-12       Impact factor: 3.835

4.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

5.  Three Emerging Coronaviruses in Two Decades.

Authors:  Jeannette Guarner
Journal:  Am J Clin Pathol       Date:  2020-03-09       Impact factor: 2.493

6.  Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2.

Authors:  Tove Hoffman; Karolina Nissen; Janina Krambrich; Bengt Rönnberg; Dario Akaberi; Mouna Esmaeilzadeh; Erik Salaneck; Johanna Lindahl; Åke Lundkvist
Journal:  Infect Ecol Epidemiol       Date:  2020-04-14

7.  Anosmia and Ageusia: Common Findings in COVID-19 Patients.

Authors:  Luigi A Vaira; Giovanni Salzano; Giovanna Deiana; Giacomo De Riu
Journal:  Laryngoscope       Date:  2020-04-15       Impact factor: 3.325

8.  High seroprevalence of SARS-CoV-2 in elderly care employees in Sweden.

Authors:  Johanna F Lindahl; Tove Hoffman; Mouna Esmaeilzadeh; Björn Olsen; Reidar Winter; Stefan Amer; Christian Molnár; Ann Svalberg; Åke Lundkvist
Journal:  Infect Ecol Epidemiol       Date:  2020-08-05
  8 in total
  6 in total

Review 1.  SARS-CoV-2 seroprevalence around the world: an updated systematic review and meta-analysis.

Authors:  Mobin Azami; Yousef Moradi; Asra Moradkhani; Abbas Aghaei
Journal:  Eur J Med Res       Date:  2022-06-02       Impact factor: 4.981

2.  Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications.

Authors:  Andrew T Levin; William P Hanage; Nana Owusu-Boaitey; Kensington B Cochran; Seamus P Walsh; Gideon Meyerowitz-Katz
Journal:  Eur J Epidemiol       Date:  2020-12-08       Impact factor: 8.082

3.  SARS-CoV-2 testing in patients with low COVID-19 suspicion at admission to a tertiary care hospital, Stockholm, Sweden, March to September 2020.

Authors:  Ana Requena-Méndez; Aikaterini Mougkou; Pontus Hedberg; Suzanne D van der Werff; Hideyuki Tanushi; Olof Hertting; Anna Färnert; Filippa Nyberg; Pontus Naucler
Journal:  Euro Surveill       Date:  2022-02

4.  Population-based prevalence surveys during the Covid-19 pandemic: A systematic review.

Authors:  Vinícius Bonetti Franceschi; Andressa Schneiders Santos; Andressa Barreto Glaeser; Janini Cristina Paiz; Gabriel Dickin Caldana; Carem Luana Machado Lessa; Amanda de Menezes Mayer; Julia Gonçalves Küchle; Paulo Ricardo Gazzola Zen; Alvaro Vigo; Ana Trindade Winck; Liane Nanci Rotta; Claudia Elizabeth Thompson
Journal:  Rev Med Virol       Date:  2020-12-04       Impact factor: 11.043

5.  Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic.

Authors:  Saro Abdella; Samuel Riou; Masresha Tessema; Ashenafi Assefa; Albab Seifu; Anna Blachman; Adugna Abera; Nicolas Moreno; Fernando Irarrazaval; Getachew Tollera; David Browning; Geremew Tasew
Journal:  EClinicalMedicine       Date:  2021-05-07

6.  Risk of SARS-CoV-2 infection in migrants and ethnic minorities compared with the general population in the European WHO region during the first year of the pandemic: a systematic review.

Authors:  Anissa Jaljaa; Susanna Caminada; Maria Elena Tosti; Franca D'Angelo; Aurora Angelozzi; Claudia Isonne; Giulia Marchetti; Elena Mazzalai; Dara Giannini; Federica Turatto; Chiara De Marchi; Angela Gatta; Silvia Declich; Scilla Pizzarelli; Salvatore Geraci; Giovanni Baglio; Maurizio Marceca
Journal:  BMC Public Health       Date:  2022-01-20       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.